Login to Your Account

Biosimilar Rules Evolve in Europe

EMA Seeks Industry Comments On IFN-Beta Draft Guideline

By Nuala Moran
BioWorld International Correspondent

Wednesday, January 25, 2012
LONDON – Pressing on with its mission of establishing regulatory pathways for more complex biosimilar drugs, the European Medicines Agency (EMA) published a draft guideline on a proposed route for approving interferon beta (IFN-beta) for treating multiple sclerosis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription